Skip navigation

Change Symbol: Lookup

PALADIN LABS INC

PALADIN LABS INC. is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets.


Symbol: N/A
Exchange(s): N/A
Industry: Consumer Products (Biotechnology & Pharmaceuticals)
5-Star Rating:
ANNUAL FINANCIALS
  Dec 31, 2012
12 Months
C$
Dec 31, 2011
12 Months
C$
Dec 31, 2010
12 Months
C$
3Yr.
Growth
% Change
Total Revenue ($000) 217,531 157,528 137,247 25.03
Earnings before Interest & Tax ($000) 65,868 45,439 40,574 65.20
Profit/Loss ($000) 59,906 50,151 29,856 93.08
Earnings per Share 2.94 2.51 1.60 81.70
Total Assets ($000) 604,517 397,913 280,623 36.94
Dividends Per Share 0.00 0.00 0.00  
Return on Com. Equity 15.50 18.19 14.10  
Employees 106 84 84  
 
Trailing 12 Month Results
  12 Months ended
Sep 30, 2013, C$
12 Months ended
Sep 30, 2012, C$
%Change
Total Revenue ($000) 284,192 188,345 50.89
Profit/Loss ($000) 50,877 62,910 -19.13
Earnings per Share 2.48 3.10 -20.00
Dividends Per Share 0.00 0.00
Number of Shares 20,405,360 20,270,836  
 
COMPANY INFORMATION
Report on Business Magazine Top 1000 Ranking
Profit:  0 Revenue: 0270 Assets:   0  
 
Key Personnel
CEO: Jonathan Goodman, President & C.E.O. (Medical le
CFO: Samira Sakhia, Chief Financial Officer
 
Contact Information
Address: 6111 Royalmount Avenue,
Suite 102,
Montreal,
QC,
H4P 2T4
Phone: 514-340-1112
Fax: 514-344-4675
Web Address: www.paladinlabs.com
E-Mail : info@paladinlabs.com
Investor Relations: Samira Sakhia, 514-340-1112
 
Company Type: Private Company Status: Active
Auditors: Ernst & Young Llp
Transfer Agent: Not Applicable
Incorporation: Cbca, Feb 25, 1983
 
 
 


All information on this site is compiled by The Globe and Mail Inc. from reliable industry sources. While all efforts are made to ensure the accuracy of the information, The Globe and Mail Inc. and its related entities assume no liability for incorrect, incomplete, or missing information from this site. Past performance is not necessarily indicative of future performance. Prior to making any investment decision, consult with a qualified investment advisor.

Copyright © 2014 The Globe and Mail Inc. All rights reserved.